Blog

Societies

Grainne O’Kane: GIANT trial in more than 70 years/ vulnerable PDAC at ASCO24

Photo taken from Grainne O’Kane/X

Jun 5, 2024, 13:27

Grainne O’Kane: GIANT trial in more than 70 years/ vulnerable PDAC at ASCO24

Grainne O’Kane, Medical Oncologist and Clinical Research Fellow at Trinity St. James’s Cancer Institute, shared a post on X:

“GIANT trial in more than 70 years/vulnerable Pancreatic ductal adenocarcinoma (PDAC) American Society of Clinical Oncology 2024 (ASCO24) as by geriatric assess.

Important to remember most on PDAC trials less than 70 years.
Dose modified Gemcitabine plus nab-Paclitaxel (GnP) versus 5‐Fluorouracil (5FU) liposomal irinotecan.
Sobering med Overall Survival (OS) by Intention-To-Treat (ITT) 4.7 versus 4.4 months.
Need to identify who can benefit and discuss with patients.”

GIANT trial

Source: Grainne O’Kane/X

5‐Fluorouracil ASCO ASCO24 cancer Gemcitabine plus nab-Paclitaxel (GnP) Grainne O’Kane OncoDaily Oncology Overall survival (OS) pancreatic ductal adenocarcinoma (PDAC)

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer